title: Molecular staging of early colon cancer on the basis of sentinel node analysis: a multicenter phase II trial.
abstract: OBJECTIVE
  Approximately 30% of patients with American Joint Committee on Cancer stage I or II colorectal cancer (CRC) develop systemic disease. We hypothesized that multimarker reverse transcriptase-polymerase chain reaction (RT-PCR) analysis of sentinel lymph nodes (SNs) draining a primary CRC could detect micrometastases not detected by conventional histopathologic analysis.
  
  
  METHODS
  In a multi-institutional study, 40 patients with primary CRC underwent dye-directed lymphatic mapping at the time of colon resection. Each dye-stained SN was tagged, and the tumor and regional nodes were resected en bloc. All lymph nodes were examined by conventional hematoxylin and eosin (HE) staining. In addition, each SN was cut into multiple sections for cytokeratin immunohistochemical (CK-IHC) staining and for RT-PCR and electrochemiluminescent detection of three markers: beta-chain human chorionic gonadotropin, hepatocyte growth factor receptor, and universal melanoma-associated antigen. Whenever possible, RT-PCR assay was also performed on primary tumor tissue. The detection sensitivity of individual markers was 10(-3) to 10(-4) microg of RNA and one to five tumor cells in 10(7) lymphocytes of healthy donors.
  
  
  RESULTS
  One to three SNs were identified in each patient. An average of 15 nodes were removed from each CRC specimen. No nonsentinel (untagged) node contained evidence of tumor if all tagged (sentinel) nodes in the same specimen were histopathology tumor-negative. HE staining of SNs identified tumor in 10 patients (25%), and CK-IHC of SNs identified occult micrometastases in four patients (10%) whose SNs were negative by HE. Of the remaining 26 patients with no evidence of SN involvement by HE or CK-IHC, 12 (46%) had positive RT-PCR results. The number of markers expressed in each SN correlated (P <.04) with the T stage of the primary tumor. There was 79% concordance in marker expression for the respective pairs (n = 38) of primary tumor and histopathologically positive SNs, and 86% (12 of 14) concordance between RT-PCR positive and histopathologically positive SNs.
  
  
  CONCLUSIONS
  Identification and focused examination of the SN is a novel method of staging CRC. CK-IHC and RT-PCR identified occult micrometastases in 53% of patients whose SNs were negative by conventional staging techniques. These ultrasensitive assays of the SN can identify patients who may be at high risk for recurrence of CRC and therefore are more likely to benefit from systemic adjuvant therapy.
authors.affiliation: Department of Molecular Oncology, John Wayne Cancer Institute, Saint John's Health Center, Santa Monica, CA 90404, USA. bilchika@jwci.org
authors.forename: A J
authors.initials: AJ
authors.lastname: Bilchik
authors.forename: S
authors.initials: S
authors.lastname: Saha
authors.forename: D
authors.initials: D
authors.lastname: Wiese
authors.forename: J A
authors.initials: JA
authors.lastname: Stonecypher
authors.forename: T F
authors.initials: TF
authors.lastname: Wood
authors.forename: S
authors.initials: S
authors.lastname: Sostrin
authors.forename: R R
authors.initials: RR
authors.lastname: Turner
authors.forename: H J
authors.initials: HJ
authors.lastname: Wang
authors.forename: D L
authors.initials: DL
authors.lastname: Morton
authors.forename: D S
authors.initials: DS
authors.lastname: Hoon
mesh_terms: D000951:Antigens, Neoplasm; D014408:Biomarkers, Tumor / Q000032:analysis*; D018997:Chorionic Gonadotropin, beta Subunit, Human; D015179:Colorectal Neoplasms / Q000097:blood / Q000378:metabolism / Q000473:pathology*; D004396:Coloring Agents; D006801:Humans; D058950:Melanoma-Specific Antigens; D009362:Neoplasm Metastasis; D009363:Neoplasm Proteins / Q000032:analysis; D009367:Neoplasm Staging / Q000379:methods*; D019859:Proto-Oncogene Proteins c-met / Q000032:analysis; D020133:Reverse Transcriptase Polymerase Chain Reaction; D021701:Sentinel Lymph Node Biopsy
chemical_list: D000951:Antigens, Neoplasm; D014408:Biomarkers, Tumor; D018997:Chorionic Gonadotropin, beta Subunit, Human; D004396:Coloring Agents; D058950:Melanoma-Specific Antigens; D009363:Neoplasm Proteins; D019859:Proto-Oncogene Proteins c-met